Understanding treatment, utilization, and costs in advanced/metastatic (Adv/Met) gastric or gastroesophageal junction cancer (GC/GEJC): Implications for episodic payment models.

被引：0
|
作者：
Kelly, Ronan Joseph
Le, Hannah
Wu, Sze-Jung
Laurie, Melissa
Raval, Amit D.
Shi, Qian
Korytowsky, Beata
机构：
[1] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[2] Bristol Myers Squibb Co, Lawrenceville, NJ USA
[3] HealthCore, Wilmington, DE USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e16035
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16035
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [31] Differences in outcome according to chemotherapy backbone and maintenance treatment in HER2 positive metastatic gastric cancer (GC) or gastroesophageal junction (GEJ)
    Martinez Lago, N.
    Candamio Folgar, S.
    Grande Ventura, C.
    Salgado Fernandez, M.
    De la Camara Gomez, J.
    Mendez Mendez, J. C.
    Arias Ron, D.
    Vazquez, F.
    Reboredo Lopez, M.
    Vidal Insua, Y.
    Grana Suarez, B.
    Jorge Fernandez, M.
    Brozos Vazquez, M. E.
    Pellon Augusto, M. L.
    Prato Varela, J.
    Gonzalez Villarroel, P.
    Fernandez Montes, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [32] Bemarituzumab for treatment of previously untreated advanced and/or metastatic gastric and gastroesophageal cancer (GC): Final analysis of a randomized phase 2 trial (FIGHT)
    Wainberg, Z.
    Kang, Y.
    Lee, K.
    Qin, S.
    Yamaguchi, K.
    Kim, I.
    Saeed, A.
    Oh, S.
    Li, J.
    Turk, H.
    Teixeira, A.
    Hitre, E.
    Udrea, A.
    Cardellino, G.
    Guardeno Sanchez, R.
    Zahlten-Kumeli, A.
    Taylor, K.
    Enzinger, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S166 - S166
  • [33] Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer
    Le, Dung T.
    Ott, Patrick A.
    Korytowsky, Beata
    Le, Hannah
    Le, T. Kim
    Zhang, Ying
    Maglinte, Gregory A.
    Abraham, Pranav
    Patel, Dhiren
    Shangguan, Tong
    Chau, Ian
    CLINICAL COLORECTAL CANCER, 2020, 19 (01) : 32 - +
  • [34] Pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer: an evidence-based review of place in therapy
    Mehta, Rutika
    Shah, Anand
    Almhanna, Khaldoun
    ONCOTARGETS AND THERAPY, 2018, 11 : 6525 - 6537
  • [35] Avelumab (anti-PD-L1) in Japanese patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): Updated results from the phase Ib JAVELIN solid tumour JPN trial
    Doi, T.
    Iwasa, S.
    Muro, K.
    Satoh, T.
    Hironaka, S.
    Esaki, T.
    Nishina, T.
    Hara, H.
    Machida, N.
    Komatsu, Y.
    Shimada, Y.
    Otsu, S.
    Shimizu, S.
    Chand, V.
    Watanabe, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [36] Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study
    Janjigian, Y. Y.
    Ajani, J. A.
    Moehler, M.
    Garrido, M.
    Gallardo, C.
    Shen, L.
    Yamaguchi, K.
    Wyrwicz, L.
    Skoczylas, T.
    Bragagnoli, A.
    Liu, T.
    Tehfe, M.
    Elimova, E.
    Li, M.
    Poulart, V.
    Lei, M.
    Kondo, K.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2021, 32 : S1329 - S1330
  • [37] Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study
    Moehler, M.
    Shitara, K.
    Garrido, M.
    Salman, P.
    Shen, L.
    Wyrwicz, L.
    Yamaguchi, K.
    Skoczylas, T.
    Campos Bragagnoli, A.
    Liu, T.
    Schenker, M.
    Yanez, P.
    Tehfe, M.
    Poulart, V.
    Cullen, D.
    Lei, M.
    Kondo, K.
    Li, M.
    Ajani, J. A.
    Janjigian, Y. Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1191 - S1191
  • [38] Fruquintinib combined with sintilimab and SOX as conversion therapy for unresectable locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): A single-arm, open-label, phase 2 clinical trial.
    Ma, Fei
    Luo, Suxia
    Zhang, Bin
    Ma, Qi
    Ji, Sheqing
    Zhang, Zhandong
    Zhang, Yonglei
    Yang, Wei
    Peng, Liangqun
    Guo, Dandan
    Ren, Jinjun
    Zhang, Yuan
    Su, Yueyue
    Li, Jing
    Liu, Wentao
    Huang, Jinxi
    Yuan, Weiwei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1) maintenance therapy versus continuation of first-line chemotherapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC).
    Moehler, Markus H.
    Ryu, Min-Hee
    Lee, Keun-Wook
    Coskun, Hasan Senol
    Wong, Rachel
    Ozguroglu, Mustafa
    Chung, Hyun-Choel
    Poltoratsky, Artem
    Tsuji, Akihito
    Yen, Chia-Jui
    Muntean, Alina
    le Sourd, Samuel
    Vaccaro, Gina M.
    Taieb, Julien
    Boku, Narikazu
    Sharma, Maitreyi
    Xiong, Huiling
    Conti, Ilaria
    Bang, Yung-Jue
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [40] TREATMENT PATTERNS, HEALTHCARE RESOURCE UTILIZATION AND COSTS, AND CLINICAL OUTCOMES AMONG ELDERLY PATIENTS WITH ADVANCED HER2-POSITIVE GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
    Wang, L.
    Wang, A.
    Valderrama, A.
    Wang, T.
    Mattera, M.
    Zhou, Z. Y.
    Shih, C. S.
    Pintova, S.
    VALUE IN HEALTH, 2024, 27 (06) : S106 - S106
12345